ARCS Australia Ltd, the peak body representing professionals in the MedTech and Pharmaceutical sector, this week announced a series of significant changes at its annual conference.
Dr Tim Boyle, CEO of ARCS Australia Ltd speaking to Australian Health Journal says, “These initiatives are central to strategy to build professionalism within the sector, increase capability and enhance the professional standing of its members.”
ARCS has launched a comprehensive Core Competency Framework tailored for the Medtech and Pharmaceutical sectors. The framework is designed to ensure members possess the specialised knowledge and skills required to excel within the sector, aiming to set benchmark for professional excellence.
“Our Core Competency Framework is a milestone in our journey to elevate professional standards for those working within the sector,” said Dr Boyle,. “It provides a structured pathway for continuous professional development common to all sectorial occupations and ensures our members are equipped with the expertise needed to meet professional demands.”
Expanding upon the Core Competency Framework, ARCS has also established international partnerships with the Association of Clinical Research Professionals (ACRP), the Regulatory Affairs Professionals Society (RAPS), and the International Society of Pharmacovigilance (ISoP) to recognise their occupation specific competency frameworks and accreditation standards. These partnerships aim to facilitate the creation of professional training pathways aligned with globally recognised best practice for sectorial occupations.
“Our alliances with ACRP, RAPS, and ISoP are pivotal in offering our members access to globally recognised professional pathways and raising the standard of Australian professionals through globally recognised professional accreditation,” said Dr Boyle.
“These collaborations help raise the bar and advance the professional standing of Australian Medtech and Pharmaceutical professionals on a global playing field.”
In recognition of professional excellence, ARCS will now issue postnominals to professional members based on their expertise. The aim of this designation is to underscore a member’s commitment to the highest standards of practice and their specialised expertise.
“The initiatives we are announcing today mark a new era for ARCS,” Dr Boyle concluded. “By establishing a robust competency framework, recognising professional excellence through postnominals, fostering international collaborations, and honouring our distinguished Fellows, we are setting a new standard for professionalism within the Australian Medtech and Pharmaceutical sectors.”
-
Stroke care advances in translated research
New nurse-led protocols for stroke patients, based on ACU research, led by the Nursing Research Institute, have resulted in changes to policy, guidelines and clinical practice in Europe and Australia. The protocols were developed through the Quality in Acute Stroke Care (QASC) Trial (published in the Lancet, 2011) to manage fever, hyperglycaemia and swallowing (FeSS) post-stroke.
-
Inaugural vaccine value chain conference talks about Team Australia
For the first time, key decision-makers and thought leaders from government, industry, academia, NGOs, and representatives from the immunisation community converged in a 2 day conference in Sydney hosted by Biointelect, highlighting the transformative potential of collaborative innovation.
-
Jack Lancaster, Evolution Surgical
Continuing the Australian Health Journal, People In Health Care series is Jack Lancaster, the CEO of Evolution Surgical, an Australian owned company established in 2014, specialising in spinal fusion implants and custom instrumentation.
Jack talks about how the company works closely with surgeons to design custom solutions manufactured to surgical requirements, and ultimately, to the benefit of the Australia patient.
